I-Mab Filed 2020 Annual Report on Form 20-F

Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced it filed its annual report on Form 20-F for the year ended December 31, 2020, with the SEC on April 28, 2021. This report is accessible via the company's investor relations website and the SEC's site. I-Mab focuses on developing novel biologics in the immuno-oncology field and aims to transition from a clinical-stage to a fully integrated global biopharmaceutical company. The company has over 15 drug candidates in its pipeline and operates globally, including in China and the U.S.

Positive

• I-Mab has a robust pipeline with over 15 clinical and pre-clinical stage drug candidates.
• The company is progressing towards becoming a fully integrated global biopharmaceutical entity.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission ("SEC") on April 28, 2021.

The annual report is available on the Company's investor relations website at ir.i-mabbiopharma.com and on the SEC's website at www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai 201210, People's Republic of China.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-filed-2020-annual-report-on-form-20-f-301279034.html

SOURCE I-Mab

FAQ

What did I-Mab announce on April 28, 2021 regarding its annual report?

I-Mab filed its annual report on Form 20-F for the year ended December 31, 2020, with the SEC.

Where can I access I-Mab's annual report?

The annual report can be accessed on I-Mab's investor relations website and the SEC's website.

What is the focus of I-Mab's business?

I-Mab focuses on the discovery, development, and commercialization of novel biologics in immuno-oncology.

How many drug candidates does I-Mab have in its pipeline?

I-Mab has over 15 clinical and pre-clinical stage drug candidates.